



Media Contacts:
Ann Marie Lisowski
(410) 902-5051
alisowski@mgmpr.com

FOR IMMEDIATE RELEASE

TEDCO Awards \$50,000 to 20/20 GeneSystems from the Maryland Technology Transfer Fund

BALTIMORE (September 9, 2002) — The **Maryland Technology Development Corporation** (TEDCO) (www.MarylandTEDCO.org) today awarded 20/20 GeneSystems \$50,000 through its Maryland Technology Transfer Fund (MTTF) program. The funding will support 20/20 GeneSystems' research at the Maryland Technology Development Center business incubator to develop its proprietary P-FILM™ (Protein-Function Identification Layered Membranes). P-FILM is used to perform analysis of diseases such as cancer, inflammatory and neurological disorders to determine the effectiveness of treatment of those particular diseases.

“The partnerships between the university research laboratories and the private sector bring valuable projects out of the labs and into the market,” said the Maryland Department of Business and Economic Development (DBED) Secretary David S. Iannucci. “The Maryland Technology Transfer Fund helps to reduce the cost of transferring technology to the business sector, contributing to the vitality of the state’s economy.”

This award follows TEDCO’s recent announcement of additional funds for the MTTF program, created to support Maryland companies wishing to develop technology-based products and/or services in collaboration with universities and federal laboratories in Maryland. The fund was made possible by a grant from DBED.

“The MTTF award allows companies, like 20/20 GeneSystems, access, funding and resources to further develop their inventions from federal labs or universities into commercially viable products,” said Phillip Singerman, TEDCO’s executive director. “Part of TEDCO’s mission is to foster the development of technology and, through this fund, we are furthering our goal.”

Applications for the fund are accepted continually and reviewed monthly by representatives from TEDCO and DBED. Applicants must submit a proposal, a commercialization plan for the technology to be developed and a scope of work and budget.

— more —

20/20 GeneSystems' ('20/20') mission is to develop innovative products for proteomics research and personalized medicine using the company's proprietary layered proteomics technology (P-FILM™). Earlier this year, 20/20 began selling its first P-FILM product (for biomedical research) worldwide through Kodak and through Wako in the Far East. 20/20 is one of the first companies to launch a completely new proteomics technology in the 21st century. Future applications of the P-FILM technology platform are in development including products for research, diagnostics, drug development, toxicology and bio-terrorism defense. A Cooperative Research and Development Agreement (CRADA) is in place with the National Cancer Institute where the foundations of 20/20's technology originated. The company also has several collaborations underway with pharmaceutical companies to develop drug discovery and diagnostic applications. For more information, visit www.2020gene.com.

The Maryland Technology Development Corporation (TEDCO) was established by the General Assembly as a tool for Maryland to use in maintaining and enhancing its reputation as a leader in technology. TEDCO's mission is to foster the development of a technology economy that will create and sustain businesses throughout all regions in the State of Maryland. Currently, TEDCO has programs that aid and promote state-funded incubators, federal and university laboratories to increase technology transfer and Maryland's eCommerce.

For more information on TEDCO visit www.MarylandTEDCO.org.

*** Businesses can obtain more information on applying for TEDCO's Maryland Technology Transfer Fund at www.MarylandTEDCO.org or by contacting Steve Fritz at 410-715-4166.**

#